share_log

Shattuck Labs | 8-K: Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs | 8-K: Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs | 8-K:Shattuck Labs公佈2024年第三季度財務業績和近期業務亮點
美股SEC公告 ·  2024/11/14 20:07

Moomoo AI 已提取核心訊息

Shattuck Labs reported Q3 2024 financial results with a net loss of $16.7M ($0.33 per share), compared to a $27.5M loss in Q3 2023. Revenue increased to $3M from $0.7M YoY, while R&D expenses decreased to $16.3M from $24.2M. The company maintained a strong cash position of $90.1M as of September 30, 2024.The company announced a strategic shift to focus on SL-325, a first-in-class DR3 blocking antibody targeting the TL1A/DR3 signaling pathway. The IND filing for SL-325 is expected in Q3 2025, with ongoing IND-enabling studies in non-human primates to evaluate safety and pharmacological profiles.Following a restructuring plan and discontinuation of SL-172154 development, Shattuck has substantially completed its workforce reduction. The company projects its current cash reserves will fund operations into 2027, extending beyond the planned Phase 1 clinical trial of SL-325.
Shattuck Labs reported Q3 2024 financial results with a net loss of $16.7M ($0.33 per share), compared to a $27.5M loss in Q3 2023. Revenue increased to $3M from $0.7M YoY, while R&D expenses decreased to $16.3M from $24.2M. The company maintained a strong cash position of $90.1M as of September 30, 2024.The company announced a strategic shift to focus on SL-325, a first-in-class DR3 blocking antibody targeting the TL1A/DR3 signaling pathway. The IND filing for SL-325 is expected in Q3 2025, with ongoing IND-enabling studies in non-human primates to evaluate safety and pharmacological profiles.Following a restructuring plan and discontinuation of SL-172154 development, Shattuck has substantially completed its workforce reduction. The company projects its current cash reserves will fund operations into 2027, extending beyond the planned Phase 1 clinical trial of SL-325.
Shattuck Labs發佈了2024年第三季度財務報告,淨虧損爲1670萬美元(每股0.33美元),相比2023年第三季度的虧損2750萬美元。營業收入同比增加至300萬美元,較去年70萬美元有所增長,而研發費用則從2420萬美元減少至1630萬美元。到2024年9月30日,公司保持了強勁的現金儲備,達9010萬美元。公司宣佈戰略轉型,專注於SL-325,這是一種針對TL1A/DR3信號通路的首創DR3阻斷抗體。SL-325的IND申請預計將在2025年第三季度提交,目前正在進行非人靈長類動物的IND賦能研究,以評估其安全性和藥理特徵。在實施重組計劃和停止SL-172154開發後,Shattuck已基本完成了員工裁減。公司預計其現金儲備可支持運營至2027年,超出SL-325計劃的第一階段臨牀試驗的時間。
Shattuck Labs發佈了2024年第三季度財務報告,淨虧損爲1670萬美元(每股0.33美元),相比2023年第三季度的虧損2750萬美元。營業收入同比增加至300萬美元,較去年70萬美元有所增長,而研發費用則從2420萬美元減少至1630萬美元。到2024年9月30日,公司保持了強勁的現金儲備,達9010萬美元。公司宣佈戰略轉型,專注於SL-325,這是一種針對TL1A/DR3信號通路的首創DR3阻斷抗體。SL-325的IND申請預計將在2025年第三季度提交,目前正在進行非人靈長類動物的IND賦能研究,以評估其安全性和藥理特徵。在實施重組計劃和停止SL-172154開發後,Shattuck已基本完成了員工裁減。公司預計其現金儲備可支持運營至2027年,超出SL-325計劃的第一階段臨牀試驗的時間。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息